Gvoke Hypopen
Payments companies reported to CMS as associated with Gvoke Hypopen. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Gvoke Hypopen, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Gvoke Hypopen
These are the largest totals companies reported as associated with Gvoke Hypopen. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jessica Adkins | Savannah, GA | Nurse Practitioner | $120,228.33 |
| John Paes | Westerville, OH | Endocrinology, Diabetes & Metabolism | $48,543.77 |
| Terrence Swade | Lombard, IL | Endocrinology, Diabetes & Metabolism | $40,696.13 |
| Bantwal Baliga | Columbus, GA | Family Medicine | $36,496.68 |
| Shawn Peavie | Cincinnati, OH | Endocrinology, Diabetes & Metabolism | $36,194.91 |
| David Kayne | Encino, CA | Internal Medicine | $35,785.16 |
| Michael Shanik | Smithtown, NY | Endocrinology, Diabetes & Metabolism | $34,105.91 |
| Robert Zimmerman | Cleveland, OH | Endocrinology, Diabetes & Metabolism | $31,762.64 |
| Laura Butz | Columbus, OH | Endocrinology, Diabetes & Metabolism | $28,653.76 |
| Martin Sarkar | Frederick, MD | Endocrinology, Diabetes & Metabolism | $22,072.54 |
Prescribed Gvoke Hypopen?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.